Research programme: stem cell therapies - FerrerAlternative Names: FAB-111; FAB-112
Latest Information Update: 21 Jan 2016
At a glance
- Originator Ferrer
- Class Stem cell therapies
- Mechanism of Action Stem cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Eye disorders
Most Recent Events
- 21 Jan 2016 Preclinical trials in Eye disorders in Spain (unspecified route)